Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
That responsibility rests with the prescribing clinician
To view or add a comment, sign in 56,933 followers
Borsonelo EC, Suchecki D, Galduroz JC
What are retatrutide and tirzepatide
Jaisinghani says that clinicians have learned from their experience prescribing Rybelsus, a GLP-1 pill that was approved for treating diabetes in 2019, that medication adherence can depend a lot on the patients preferences
2 people out of 100 who received drug X experienced a heart attack after 3 years 4 people out of 100 who received the placebo experienced a heart attack after 3 years We divide 4/100 to get the baseline absolute risk in this placebo group (often referred to as the control group), which is 4% We then divide 2/100 to get the absolute risk in the group taking the medication (often referred to as the exposure or intervention group), which is 2% To understand the relative risk, we divide the exposed group with the placebo group: 2%/4% = 50% We can then calculate the difference between 2% and 4% to understand the absolute risk, which would be 2% This means that drug X causes a 50% relative drop in the rate of heart attacks compared to the placebo group
